Structure Therapeutics: $1.3B Cash Fuels Obesity Pipeline

Structure Therapeutics highlighted its oral obesity pipeline advancements at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 10, 2026. The company reported that oral GLP-1 drugs are rapidly entering the market, capturing 17% of the market share, primarily through new patient acquisition. Structure's oral GLP-1 candidate, aleniglipron, has shown a 16% weight loss at eight weeks, positioning it favorably against competitors.

The company also presented new human data for its oral amylin candidate, ACCG-2671. This data revealed a notable 6-day half-life and a 3.3% weight loss by day 24 at the 10 mg dose. Importantly, no adverse events were observed at lower doses (1 mg and 2 mg), indicating a potentially favorable safety profile.

Financially, Structure Therapeutics maintains a robust position with $1.3 billion in cash as of June 30, 2026. This strong balance sheet is projected to support major clinical milestones, including Phase III trials for aleniglipron through 2028. The company is also exploring strategic partnerships to further advance its portfolio.

Looking ahead, Structure Therapeutics has several key data readouts planned. By the end of 2024, the company expects to initiate clinical development for its second DACRA molecule, ACCG-3535. In the first half of 2027, results from the 12-week multiple ascending dose study for ACCG-2671 are anticipated.